Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
OPALINE : A Study Of Morbidity And Mortality At 2 Years
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 144
- Registration Number
- NCT02264665
- Locations
- 🇫🇷
Groupe Hospitalier Cochin, Paris Cedex, France
🇫🇷CHU de Strasbourg - Hopital de Hautepierre / Service de Medecine Interne et Nutrition, Strasbourg Cedex, France
🇫🇷Hopital Foch, Onco Hermatologie, Suresnes cedex, France
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
- Conditions
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 15
- Registration Number
- NCT02239952
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1390
- Registration Number
- NCT02231749
- Locations
- 🇮🇱
Local Institution - 0120, Haifa, Israel
🇺🇸Local Institution - 0057, La Jolla, California, United States
🇺🇸Local Institution - 0067, Stanford, California, United States
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 80
- Registration Number
- NCT02230176
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- Conditions
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT02164240
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 5
- Registration Number
- NCT02071641
- Locations
- 🇳🇱
VU Medical Center, Amsterdam, Netherlands
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
- Conditions
- Iris MelanomaStage IIA Intraocular MelanomaCiliary Body and Choroid Melanoma, Small SizeStage IIIB Intraocular MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeStage IIIC Intraocular MelanomaStage I Uveal Melanoma AJCC V7Stage II Uveal Melanoma AJCC V7Stage I Intraocular MelanomaStage IIIA Intraocular Melanoma
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 210
- Registration Number
- NCT02068586
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02060370
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Lineberger Cancer Center, Chapel Hill, North Carolina, United States
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 101
- Registration Number
- NCT02058901
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT01984242
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of California, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.